Matej
Oresic
InFLAMES Flagship
Professor, Turku Bioscience Centre
Ph.D.
Areas of expertise
Systems biology
bioinformatics
metabolomics
lipidomics
biophysics
systems medicine
computational biology
Biography
Professor Matej Orešič holds a PhD in biophysics from Cornell University. He is Professor of Medical Sciences with Specialization in Systems Medicine at School of Medical Sciences (Örebro University, Sweden), Group Leader in Systems Medicine at the Turku Bioscience Centre (University of Turku, Finland), and Guest Professor at the Oil Crops Research Institute Chinese Academy of Agricultural Sciences (Wuhan, PR China). His main research areas are metabolomics applications in biomedical research and integrative bioinformatics. He is particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities, with specific focus on obesity and diabetes and their co-morbidities. Dr. Orešič has also initiated the popular MZmine open source project, leading to popular software for metabolomics data processing. Previosuly, Dr. Orešič was principal investigator at Steno Diabetes Center (Gentofte, Denmark), research professor at VTT Technical Research Centre of Finland (Espoo, Finland), head of computational biology and modeling at Beyond Genomics, Inc. (Waltham/MA) and bioinformatician at LION Bioscience Research in Cambridge/MA. In 2016, Dr. Oresic received the Lifetime Honorary Fellow award from the Metabolomics Society.
Research
Our main research area is systems medicine, particularly metabolomics applications in biomedical research and related integrative bioinformatics. Specifically, we am particularly interested in the identification of disease vulnerabilities associated with different metabolic phenotypes and the underlying mechanisms linking these vulnerabilities with the development of specific disorders or their co-morbidities. Such in depth understanding of the metabolic phenotypes in health and disease is crucial if one is to implement personalized medicine. Dr. Orešič initiated the popular MZmine open source project, leading to popular software for metabolomics data processing.
Main ongoing projects:
Strategic Research Agreement, Juvenile Diabetes Research Foundation (9/2016-9/2018): Metabolomic and Proteomic markers staging progression to type 1 diabetes in autoantibody positive children – PI
Strategic Research Agreement, Juvenile Diabetes Research Foundation (9/2016-9/2018): Mother-infant interactions in relation to potential biomarkers of beta-cell autoimmunity and type 1 diabetes – PI
Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research (2012-2017) - PI
Strategic Research Agreement, Juvenile Diabetes Research Foundation (Integrative multi-omic study of early progression to type 1 diabetes; 2014-2017) - PI
pHealth Programme, multi-PI collaborative project, Academy of Finland (Personalised medicine to predict and prevent Type 1 Diabetes; 9/2015-8/2019) – Co-PI
EU H2020 EPoS (Elucidating Pathways of Steatohepatitis) - Workpackage leader
EU FP7 METSY (Integrated neuroimaging and metabolic platform for characterisation of early psychosis and prediction of patient outcomes) - Coordinator
Publications
The PNPLA3-I148M variant increases polyunsaturated triglycerides in human adipose tissue (2020)
Liver International
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Correction: Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state (2020)
Journal of Biological Chemistry
(O2 Muu julkaisu )
MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans (2020)
Journal of Hepatology
(Kirjoitus tai data-artikkeli tieteellisessä aikakauslehdessä (B1))
Metabolic Signatures of the Exposome-Quantifying the Impact of Exposure to Environmental Chemicals on Human Health (2020)
Metabolites
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease (2020)
JCI Insight
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Publisher Correction: Building an international consortium for tracking coronavirus health status (2020)
Nature Medicine
(O2 Muu julkaisu )
Prenatal exposure to perfluoroalkyl substances modulates neonatal serum phospholipids, increasing risk of type 1 diabetes (2020)
Environment International
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis (2020)
Science Translational Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease (2019)
Cell
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )
Circulating metabolites in progression to islet autoimmunity and type 1 diabetes (2019)
Diabetologia
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))